polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
SUFLAVE is an oral bowel preparation solution containing polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride. It is indicated for cleansing the colon prior to colonoscopy and other gastrointestinal procedures. The formulation works by osmotic action to evacuate the bowel without significant net absorption or secretion of ions.
Product is in peak commercial phase with modest Part D spending; team size and growth trajectory depend on market penetration in the bowel prep segment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SUFLAVE is a recently approved bowel preparation agent with no current linked job postings, indicating early-stage commercial infrastructure build-out. Career opportunities will emerge in brand management, specialty sales targeting gastroenterology practices, and reimbursement support as market penetration accelerates.
Worked on SUFLAVE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo